Pharma sales in Pharmerging Markets: why strategy must evolve, not just expand
“Pharmerging” markets—fast‑growing economies such as India and others—are now the growth engine of the global pharmaceutical industry, with annual market expansion estimated at around 14–15% compared with low single‑digits in mature markets. As margins tighten in the US, Europe and Japan, global and local pharma companies are pouring promotional budgets into these high‑potential countries, often spending up to one‑third of their income on marketing and sales activities.
A qualitative study, shows that pharma sales strategies in such settings are a mix of aggressive but legal promotion and more problematic practices that exploit regulatory gaps, weak governance and under‑resourced health systems. Physicians, pharmacists and even patients are targeted through gifts, sponsorships, educational events and subtle scientific messaging; yet prescribers are often under‑trained in how to critically evaluate promotional claims and underestimate marketing’s influence on their own decisions. For pharmaceutical leaders and investors, this raises an urgent strategic question: how can companies compete and grow in pharmerging markets without deepening ethical risks, policy backlash and long‑term reputational damage?
Growth in “mature” pharma markets slowed to around 2–3% in 2008, while “pharmerging” markets recorded 14–15% growth, rapidly shifting the global sales focus.
- Pharmerging markets grow ~14–15% annually, attracting intensive promotional spend and making them central to global pharma revenue strategies.
- Sales tactics in these markets target prescribers, pharmacists, patients and society at large, and can range from conventional detailing to ethically problematic practices like biased “education” and inducements.
- Without stronger national drug policy, prescriber education and tighter marketing frameworks, structural gaps will continue to be exploited, undermining rational use of medicines and long‑term trust in the industry.
Key Sales Strategies for Pharmerging Countries
Localized Market Segmentation:
Segmenting the market based on demographics, disease prevalence, and healthcare access enables pharmaceutical firms to target efforts efficiently. Understanding rural vs. urban healthcare needs and adjusting product offerings accordingly helps maximize reach.
Building Strong Local Partnerships:
Collaborations with local distributors, healthcare providers, and government agencies can enhance market penetration. These partnerships often facilitate smoother regulatory approvals and distribution, while reinforcing credibility.
Investing in Education and Awareness:
Many pharmerging markets face information gaps among healthcare providers and patients. Running educational campaigns, training healthcare professionals, and supporting awareness initiatives enhance product adoption and foster long-term loyalty.
Leveraging Digital Tools and Analytics:
Digital engagement platforms, telemedicine, and data analytics help pharmaceutical companies understand patient behavior and tailor their sales outreach effectively. This approach is especially valuable in regions with widespread mobile connectivity but limited traditional healthcare access.
Flexible Pricing and Access Models:
Given diverse economic conditions, companies should design adaptable pricing strategies, including tiered pricing, patient assistance programs, or subscription models, to improve affordability and access.
"Interviews with physicians showed that sales strategies, both legal and illegal, are universally employed, targeting prescribers, patients, pharmacists, and the public, often using scientific and ethical principles as tools instead of safeguards."
Adapting Sales Forces to Local Realities
Pharmerging markets often require a departure from traditional sales force models. Successful companies invest in training sales teams to navigate cultural nuances and regulatory complexities. Sales representatives must be skilled not only in product knowledge but also in relationship-building and education. Utilizing local hires familiar with the market’s specific challenges enhances communication and trust with healthcare
Summary
Pharmerging markets offer significant opportunities for pharmaceutical sales but also pose ethical challenges. As mature markets stagnate, high growth in countries like Turkey makes these regions key targets, with companies allocating substantial revenue to promotion. Tactics beyond traditional detailing, such as sponsored education and influenced research, can blur the line between information and inducement, impacting physician prescribing.
- For pharma leaders and investors, three points are critical:
First, commercial success hinges on responsible navigation of weak regulations and information imbalances. - Second, underinvestment in education and infrastructure leaves health systems susceptible to distorted prescribing and increased long-term costs.
- Third, strategic advantage increasingly relies on aligning sales growth with national drug policies, transparency, and rational drug use, rather than exploiting regulatory gaps.
-
[…] Linking Training Activities to Sales Outcomes […]
Leave feedback about this